Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1992-9-8
|
| pubmed:abstractText |
Anti-CD2 monoclonal antibodies (mAb) were used to influence graft survival in two transplantation models. Xenogeneic rat islets were transplanted intraportally into mice. Anti-CD2 mAb prolonged xenograft survival and was synergistic with UVB irradiation in prolonging survival. Anti-CD2 mAb was also more potent than an anti-CD4 mAb in this model. Allogeneic cardiac grafts were transplanted across an entire H-2 difference and anti-CD2 mAb prolonged allograft survival in a dose-dependent fashion. Kinetic experiments revealed that anti-CD2 mAb was most potent when administered at the time of allografting. A delay in administration of mAb markedly reduced its immunosuppressive effects. Furthermore, additional doses of mAb given after the initial doses provided no increased immunosuppression and anti-CD2 mAbs did not delay rejection of second-set allografts. These findings support the notion that anti-CD2 mAbs interfere with afferent immunity and that CD2 is most important during the initial steps of an immune response. Investigation of the effect of anti-CD2 mAb on cellular immune functions demonstrated, in agreement with previous results, that it caused antigenic down-modulation of CD2 with relative sparing of CD3, CD4, and CD8 cell surface expression. Concomitantly the MLR, CTL, and NK responses were suppressed.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0041-1337
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
54
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
286-91
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1353913-Animals,
pubmed-meshheading:1353913-Antigens, CD2,
pubmed-meshheading:1353913-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:1353913-Cytotoxicity, Immunologic,
pubmed-meshheading:1353913-Graft Survival,
pubmed-meshheading:1353913-Heart Transplantation,
pubmed-meshheading:1353913-Immunosuppression,
pubmed-meshheading:1353913-Islets of Langerhans Transplantation,
pubmed-meshheading:1353913-Killer Cells, Natural,
pubmed-meshheading:1353913-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:1353913-Lymphocyte Depletion,
pubmed-meshheading:1353913-Lymphocyte Subsets,
pubmed-meshheading:1353913-Mice,
pubmed-meshheading:1353913-Mice, Inbred Strains,
pubmed-meshheading:1353913-Receptors, Immunologic,
pubmed-meshheading:1353913-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:1353913-Transplantation, Heterologous,
pubmed-meshheading:1353913-Transplantation, Homologous
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies.
|
| pubmed:affiliation |
Department of Surgery, Medical University of South Carolina, Charleston 29425.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|